Videos

Future Perioperative Strategies in Non-Small Cell Lung Cancer

Varun Narendra, MD, describes a clinical trial that studied whether pediatric-inspired ALL regimens could be used in older adults with Philadelphia chromosome–positive ALL.

Charu Aggarwal, MD, MPH;Benjamin P. Levy, MD;Harvey I. Pass, MD;Heather Wakelee, MD

Emerging Data and Future Directions in UC

Before closing out their discussion on non–small cell lung cancer, experts share excitement for possible improvements in the setting of perioperative therapy.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

ASCO GU 2022 Updates: PARP Inhibitors in First-Line and Subsequent UC Settings

Experts highlight emerging data and novel regimens that have the biggest potential to impact treatment and management of patients with urothelial cancer.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

Targeted and IO Therapy in EGFR Exon 19 Deletion–Positive NSCLC

Experts comment on the utility of PARP inhibitors in UC and discuss data presented at ASCO GU 2022.

Charu Aggarwal, MD, MPH;Benjamin P. Levy, MD;Harvey I. Pass, MD;Heather Wakelee, MD

Uday R. Popat, MD, on the Future of Post-Transplant Cyclophosphamide to Prevent GVHD After Transplant for AML/MDS

Experts consider when and if it would be appropriate to utilize targeted or immunotherapy in patients with EGFR exon 19 deletion–positive NSCLC.

Uday R. Popat, MD

Case Presentation: A 74-Year-Old Woman with Relapsed/Refractory Multiple Myeloma

Uday R. Popat, MD, spoke about where he sees future research efforts headed regarding post-transplant cyclophosphamide to prevent graft-vs-host disease for patients with acute myeloid leukemia after transplant and how these results could impact the standard of care.

$Case Presentation: A 74-Year-Old Woman with Relapsed/Refractory Multiple Myeloma$

Sagar Lonial, MD;Nisha Joseph, MD;Jonathan L. Kaufman, MD;Ajay K. Nooka, MD

Choosing a Combination Therapy for Renal Cell Carcinoma Before and After CLEAR Data

Experts discuss the case of a woman with relapsed/refractory multiple myeloma and the available treatment options, including novel BCMA-targeted agents.

Brian Shimkus, MD;Tom Powles, MBBS, MRCP, MD

Blood-Based MRD Testing and Transplant-Ineligible Multiple Myeloma

Brian Shimkus, MD, discusses how he chose between RCC combination therapies before CLEAR trial data, and how the data influences his decisions now.

Sagar Lonial, MD;Nisha Joseph, MD;Jonathan L. Kaufman, MD;Ajay K. Nooka, MD

Dose Reductions and Treatment Breaks on Lenvatinib Therapy

Key opinion leaders describe the role of blood-based MRD testing in the transplant-ineligible multiple myeloma treatment landscape.

Tom Powles, MBBS, MRCP, MD;Brian Shimkus, MD

Key GALAXY Takeaways and Clinical Implications

Dr Brian Shimkus describes how he doses lenvatinib for renal cell carcinoma treatment.

Stacey A. Cohen, MD;Mark Lewis, MD

GALAXY: Cumulative ctDNA Clearance Rates by ACT Receipt

Stacy A. Cohen, MD and Mark Lewis, MD share key takeaways from the GALAXY study and discuss the clinical implications of using ctDNA-based assays for patients with CRC.

Stacey A. Cohen, MD;Mark Lewis, MD

Sara Hurvitz, MD, Discusses the Full Approval of Second-Line T-DXd in HER2+ Breast Cancer

Experts describe cumulative ctDNA clearance rates in patients with stage I-IV disease who did or did not receive adjuvant chemotherapy in the GALAXY study.

Sara A. Hurvitz, MD

The Importance of Team-Based Management and Patient Communication

Sara Hurvitz, MD, spoke about to recent approval of fam-trastuzumab deruxtecan-nxki in the second-line setting for patients with HER2-positive breast cancer.

David Aggen, MD, PhD;Robert S. Alter, MD;Arnab Basu, MD, MPH, FACP;Mehmet Asim Bilen, MD;Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center

May 25th 2022

Robert Alter, MD, comments on the importance of team-based care and frequent, timely communication in managing patients with RCC.

Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer

David Aggen, MD, PhD;Robert S. Alter, MD;Arnab Basu, MD, MPH, FACP;Mehmet Asim Bilen, MD;Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center

May 25th 2022

David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.

Alina Markova, MD, on the Safety Profile of Topical Ruxolitinib for Cutaneous Chronic GVHD

Alina Markova, MD

May 25th 2022

Alina Markova, MD, highlights the safety and tolerability of topical ruxolitinib INCB018424 phosphate 1.5% cream for patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.

Case Presentation 2: Transplant-Ineligible NDMM and Treatment With the DRd Regimen

Shaji Kumar, MD, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic;David Dingli, MD, PhD;Prashant Kapoor, MD

ELEVATE-RR: Efficacy Data

Experts review a second patient case wherein transplant-ineligible newly diagnosed multiple myeloma was treated with the daratumumab, lenalidomide and dexamethasone regimen and how updated data from the MAIA trial can be incorporated into clinical practice.

Michael R. Bishop, MD;Bruce B. Bank, MD

Role for Transplantation and Maintenance Therapy in NDMM

Experts discuss efficacy data from the ELEVATE-RR trial on the Bruton tyrosine kinase inhibitors acalabrutinib vs ibrutinib.

Shaji Kumar, MD, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic;David Dingli, MD, PhD;Prashant Kapoor, MD

Patient Characteristics in ELEVATE-RR

Considerations for assessing eligibility of patients for transplantation for NDMM and how maintenance therapy may be initiated in the post-transplant setting.

Michael R. Bishop, MD;Bruce B. Bank, MD

Uday R. Popat, MD, on Post-Transplant Cyclophosphamide Following Myeloablative Busulfan as GVHD Prophylaxis

Dr Bishop comments on the characteristics of the patients with CLL who were enrolled in the ELEVATE-RR trial.

Uday R. Popat, MD

Role of Neurooncologists in Management of HER2+ Breast Cancer and Brain Metastases

Uday R. Popat, MD, spoke about how use of post-transplant cyclophosphamide vs tacrolimus plus methotrexate to prevent graft-vs-host disease following matched donor hematopoietic cell transplantation for acute myeloid leukemia could impact the standard of care.

Sara Hurvitz, MD;Ruta Rao, MD;Stefania Maraka, MD

A Pediatric Regimen for Older Adults and Adolescents with ALL: CALGB 10403 Study

A look at the evolving role of neurooncologists in the treatment of patients with HER2+ breast cancer and brain metastases and future perspectives in the management of this patient population.

Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Reem Akel, MD;Meghan Thompson, MD;Varun Narendra, MD;Xiaoli Mi, MD

ASCO GU 2022 Updates: Antibody-Drug Conjugates

Varun Narendra, MD, presents the CALGB 10403 clinical trial on the use of a pediatric regimen in older adolescents and young adults with ALL.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

Trastuzumab Deruxtecan Treatment for Metastatic HER2+ Breast Cancer with Brain Metastases

Guru Sonpavde, MD, introduces emerging antibody-drug conjugates for treating metastatic UC, and reviews recent ASCO GU 2022 data on these regimens.

Sara Hurvitz, MD;Stefania Maraka, MD;Ruta Rao, MD

ASCO GU 2022 Updates: Trials on Combination Immunotherapy versus Chemotherapy

Experts have a conversation of the use of trastuzumab deruxtecan therapy for patients with progressive brain metastases while weighing common toxicities and clinical trial data.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

Cross Q&A: Team Moffitt Marrowvingians

Petros Grivas, MD, PhD, transitions the panel discussion to focus on clinical trial data on combination immunotherapy versus platinum chemotherapy regimens that were recently presented at ASCO GU 2022.

Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Reem Akel, MD;Meghan Thompson, MD;Varun Narendra, MD;Xiaoli Mi, MD